Core Viewpoint - Yonghe Intelligent Control Co., Ltd. is divesting all its investments in private oncology hospitals, marking a complete exit from the healthcare sector due to ongoing financial struggles and poor performance of its medical assets [2][3][5]. Group 1: Divestment Details - Yonghe Intelligent Control has initiated the public transfer of 100% equity in its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a starting price of no less than 35.93 million yuan [3][4]. - This divestment is part of a broader strategy, as Yonghe has already attempted to sell its stakes in three other oncology hospitals since 2020, including Dazhou Medical Oncology Hospital, Liangshan High-tech Oncology Hospital, and Xi'an Medical Oncology Hospital [3][4]. - The financial performance of Kunming Medical has been poor, with revenues of 11.58 million yuan and a net loss of 6.59 million yuan for the first seven months of 2025, contributing to Yonghe's decision to sell [3][6]. Group 2: Financial Performance - Yonghe Intelligent Control's main business includes fluid control products, oncology precision radiation treatment, and photovoltaic battery production. The company reported a revenue of 1.01 billion yuan in 2021, marking a 55.71% increase [5]. - However, the company's financial situation deteriorated significantly from 2022 to 2024, with revenues declining from 990 million yuan in 2022 to 823 million yuan in 2024, and net losses increasing from 26.19 million yuan to 297 million yuan during the same period [6]. - The decline in performance is attributed to reduced income from the valve and fitting business, lower product gross margins, and high depreciation and labor costs [6][7]. Group 3: Strategic Shift - Following the divestment of its medical assets, Yonghe Intelligent Control is expected to refocus on its core business operations. The company has not yet communicated its future strategic direction or potential new growth areas [7].

Group 1 - The core viewpoint of the news is that Yonghe Intelligent Control has shown significant stock performance with a year-to-date increase of 54.90%, despite a recent slight decline in the last five trading days [1] - As of November 25, the stock price reached 6.32 CNY per share, with a total market capitalization of 2.817 billion CNY [1] - The company has experienced a net outflow of main funds amounting to 603,300 CNY, with large orders showing a buy of 27.30 million CNY and a sell of 25.87 million CNY [1] Group 2 - Yonghe Intelligent Control operates in the mechanical equipment sector, specifically in general equipment and metal products, with a focus on the healthcare industry and fluid control business [2] - As of September 30, the number of shareholders increased by 54.10% to 31,300, while the average circulating shares per person decreased by 35.11% to 13,876 shares [2] - For the period from January to September 2025, the company reported a revenue of 582 million CNY, a year-on-year decrease of 7.25%, and a net profit attributable to the parent company of -60.46 million CNY, a year-on-year increase of 20.65% [2] Group 3 - Since its A-share listing, Yonghe Intelligent Control has distributed a total of 200 million CNY in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Yonghe Intelligent Control announced the decision to publicly transfer 100% equity of Kunming Medical Oncology Hospital Co., Ltd. through a public listing on the Southwest United Property Rights Exchange [2] Group 1 - The fifth session of the board of directors and the supervisory board will hold temporary meetings on November 18, 2025, to review the proposal for the equity transfer [2] - The initial listing price for the 100% equity of Kunming Medical is set at RMB 35.9277 million [2] - The public listing announcement period is from November 24, 2025, to December 5, 2025 [2]

Core Viewpoint - The company, Yonghe Intelligent Control, has announced the public transfer of 100% equity in its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a starting price of RMB 35.9277 million [1] Group 1: Company Actions - The company will hold the 26th temporary meeting of the fifth board of directors and the 20th temporary meeting of the fifth supervisory board on November 18, 2025, to review the proposal for the equity transfer [1] - The company has submitted an information disclosure application to the Southwest United Property Rights Exchange, which has been accepted [1] - The public listing period for the 100% equity of Kunming Medical Oncology Hospital is from November 24, 2025, to December 5, 2025 [1] Group 2: Financial Details - The initial listing price for the 100% equity of Kunming Medical Oncology Hospital is set at RMB 35.9277 million [1]

Group 1 - The company has approved the public transfer of 100% equity in its wholly-owned subsidiary, Kunming Medical Oncology Hospital Co., Ltd [1] - The initial listing price for the 100% equity of Kunming Medical is set at 35.9277 million yuan, with the listing period from 2025 to 2025 [1] - The transaction carries uncertainties regarding its success, potential buyers, and pricing, with risks of multiple price reductions and lack of bidders [1]

证券代码：002795 证券简称：永和智控 公告编号：2025-066 永和流体智控股份有限公司 关于公开挂牌转让昆明医科肿瘤医院有限公司100%股权的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 永和流体智控股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开第五 届董事会第二十六次临时会议、第五届监事会第二十次临时会议，审议通过了《关于 拟公开挂牌转让昆明医科肿瘤医院有限公司 100%股权的议案》，同意公司在产权交 易所公开挂牌转让全资孙公司昆明医科肿瘤医院有限公司（以下简称"昆明医科"） 100%股权，并同意授权公司董事长或董事长授权的代理人负责具体实施该事项。具 体内容详见公司于 2025 年 11 月 19 日在巨潮资讯网（http://www.cninfo.com.cn）、 《证券时报》和《证券日报》刊登的《关于拟公开挂牌转让昆明医科肿瘤医院有限公 司 100%股权的公告》（公告编号：2025-062）。 二、交易进展情况 截至本公告披露日，公司已向西南联合产权交易所（以下简称"西南联交所"）提 交《 ...

AI and Technology - Google has released a new image model, attracting attention in the AI sector [2] - 360, a leader in AI search, has developed the 360 Smart Brain with ten core capabilities and hundreds of detailed functions, reporting a net loss of 120 million in Q3, narrowing from mid-year losses [2] - Jiuxi Software has launched its new generation large model application management platform, Nvwa GPT, which integrates and provides capabilities for large model management and intelligent orchestration [2] Aerospace and Defense - Japan has announced the deployment of missiles in sensitive areas, impacting defense-related companies [2] - Aerospace Power, a subsidiary of the Aerospace Science and Technology Group, has seen stock performance with a recent increase [2] - China Shipbuilding Industry Group, which controls multiple defense-related companies, is the only military ship production base in South China [2] E-commerce and Retail - Alibaba's "Qianwen" app has surpassed 10 million downloads in its first week of public testing [3] - Sanjiang Shopping, the largest local supermarket chain in Zhejiang, has Alibaba as its second-largest shareholder and is involved in the sale of prepared dishes [3] - DataPort, a leading data center company, provides infrastructure solutions and serves major internet companies like Alibaba, Tencent, Baidu, and NetEase [3] Real Estate - Multiple regions have issued notifications to promote the stable and healthy development of the real estate market [5] - Everbright Jiabao, a real estate development company under Everbright Group, focuses on non-performing asset management in Zhejiang [5] Automotive - GAC Group has officially launched its all-solid-state battery pilot production line [5] - Jinlong Automobile, a major bus manufacturer, has partnered with Baidu to produce China's first commercial-grade autonomous micro-circulation vehicle [5] Renewable Energy - Guosheng Technology, a top global manufacturer of heterojunction products, is focusing on high-efficiency solar cells and has plans for a solid-state battery project [6] - Hemei Group's subsidiary is investing in a green hydrogen project with an estimated total investment of around 700 million [6] Food and Beverage - Xinhua Du, a leading e-commerce platform for liquor, has seen stock performance with a recent increase [4] - Hasi Lian, a beauty brand, is focusing on skincare products and has developed a series of medical-grade dressings [5]

Group 1 - The core point of the article highlights the significant stock price increase of Yonghe Intelligent Control (002795.SZ), which rose by 9.95% to a latest price of 6.19 yuan, with a total market capitalization of 2.759 billion yuan and a trading volume of 2.93 billion yuan [1] - The market speculation around the company is attributed to its ongoing asset structure optimization, particularly the divestment of its loss-making medical assets, including the complete exit from the private oncology hospital sector [1] - The company announced on November 18 its intention to publicly transfer 100% equity of Kunming Medical Oncology Hospital at a minimum price of 35.93 million yuan, which represents a significant discount of approximately 70% from the acquisition cost of 108 million yuan in 2020 [1] Group 2 - The company's main business segments include fluid intelligent control products, healthcare, and solar cell production [2] - For the first three quarters of 2025, the company reported total operating revenue of 582 million yuan, a year-on-year decrease of 7.25%, and a net profit loss of 60.46 million yuan [2] - Following the lifting of a judicial freeze on 2 million shares held by the controlling shareholder, 800,000 shares were immediately frozen again by the Chengdu Jin Niu District People's Court, representing 1.86% of the shares held, with a total of 0.18% of the company's total shares being subject to judicial freeze [2]

Core Points - Yonghe Zhikong plans to publicly transfer 100% equity of Kunming Medical Oncology Hospital with a minimum listing price of 35.93 million yuan, marking a complete exit from the healthcare sector after divesting all four private hospitals since 2020 [2] - The acquisition of Kunming Medical was made in 2020 for 108 million yuan, resulting in goodwill of 71.15 million yuan, with the current listing price reflecting a discount of approximately 70% compared to the initial acquisition cost [2] - The company has also listed for sale the equity stakes of its other hospitals, including Dazhou Medical Oncology Hospital (95% stake at 27.68 million yuan), Liangshan High-tech Oncology Hospital (70% stake at 9.37 million yuan), and Xi'an Medical Oncology Hospital (73% stake) along with a debt claim of 14.93 million yuan [2] - The divestment aims to optimize the company's industrial structure and improve the quality of development [2] Financial Performance - After the acquisition, both Kunming Medical and Xi'an Medical reported losses in 2022, while Dazhou Medical and Liangshan High-tech also faced losses in 2023, with all four hospitals continuing to incur losses into the first half of 2024 [3]

Core Viewpoint - Yonghe Intelligent Control is facing significant challenges in asset divestiture and ongoing financial losses, indicating a deteriorating business situation and lack of investor interest in its assets [1][2][3]. Group 1: Asset Transfer Attempts - Yonghe Intelligent Control announced the public transfer of 51% equity in Taixing Pule and all debts owed by Taixing Pule, with an initial listing price of RMB 30.49 million, but failed to attract any interested buyers [1][3]. - Following the lack of interest, the company plans a second round of asset transfer at a reduced price of RMB 24.39 million, reflecting a 20% decrease from the initial price [1][3]. - The company's previous attempt to transfer shares held by its actual controller was also unsuccessful, as the buyer failed to make the required payment, rendering the agreement void [1][9]. Group 2: Financial Performance - Yonghe Intelligent Control has experienced a continuous decline in revenue since 2022, with reported revenues of RMB 9.90 billion, RMB 9.48 billion, and RMB 8.23 billion for the years 2022, 2023, and 2024 respectively, showing year-on-year declines of -1.86%, -4.19%, and -13.19% [2][7]. - The company reported net losses of RMB 261.87 million, RMB 1.56 billion, and RMB 2.97 billion for the same years, with losses increasing significantly year-on-year [2][7]. - For the first three quarters of 2025, Yonghe Intelligent Control reported revenues of RMB 5.82 billion, a decrease of 7.25% year-on-year, and a net loss of RMB 60.46 million, although this loss was less than the previous year's figure [8]. Group 3: Company Background and Business Operations - Yonghe Intelligent Control's main business includes water and heating valve fittings, tumor precision radiation treatment, and photovoltaic cell operations, with a focus on brass and copper products [7]. - The company acquired a 51% stake in Taixing Pule in late 2022 for RMB 31.22 million, aiming to enter the photovoltaic cell industry, but has since struggled with the performance of this investment [5][8]. - As of May 31, 2025, Taixing Pule reported a net asset value of -RMB 304 million and a debt of RMB 185 million, leading to a high debt-to-asset ratio of 211% [4].